CRI: Innovative AAV-Based Gene Therapy for Rare Neurogenetic Diseases
Targeting Unmet Needs: Innovative AAV-Based Gene Therapy for Rare Neurogenetic Diseases
Join the Children's Research Institute and Tierra Bobo, PhD, a research assistant professor in the UNC School of Medicine Department of Pediatrics, Division of Genetics & Metabolism, for a seminar on innovative AAV-based gene therapy for rare neurogenetic diseases. Bobo's research focuses on strategies to overcome key barriers in gene therapy, including immune exclusion due to pre-existing antibodies and the development of bystander-mediated cross-correction via extracellular vesicle (EV) mRNA cargo. She earned her PhD in Human Molecular Genetics from The Ohio State University, where she studied the epigenetic regulation of aging-related lung diseases, followed by postdoctoral training in epigenetics and extracellular vesicle biology at West Virginia University, and gene therapy at UNC. Her long-term goal is to translate innovative gene therapy platforms into effective and accessible treatments for children with neurodegenerative diseases.
Participate in the seminar at 3116 Mary Ellen Jones Building (with lunch provided). A zoom option is available by request.